Louise Koopman

Company: Genmab

Job title: Associate Director, Translational Research

Seminars:

In Vitro and In Vivo Studies Establish DuoBody®-CD3xB7H4 as a Novel Drug Candidate for The Treatment Of Solid Cancers 9:30 am

DuoBody®-CD3xB7H4 is an Fc-silenced bispecific antibody designed to induce T-cell mediated cytotoxicity of B7H4+ tumor cells Preclinical and PD biomarker studies suggest DuoBody-CD3×B7H4 enhances T-cell activation, proliferation, and production of cytokines and effector molecules DuoBody®-CD3xB7H4 is currently being investigated in a first-in-human trial for the treatment of solid tumors known to express B7H4Read more

day: Day One